Education
About Us
Working with TipRanks
Follow Us
Nicholas A.J. Botwood Insider Profile
4 Followers
Nicholas A.J. Botwood, Head of R&D, CMO at Syndax Pharmaceuticals, holds 35.16K shares in Syndax Pharmaceuticals (Ticker: SNDX). Most recently, Nicholas A.J. Botwood Bought $11,765 shares of Syndax Pharmaceuticals on May 19, 2025 for an estimated value of 105.77K.
Nicholas A.J. Botwood has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Nicholas A.J. Botwood's holdings
Insider Roles
Head of R&D, CMO
Roles that Nicholas A.J. Botwood holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Nicholas A.J. Botwood
Nicholas A.J. Botwood's Trading History
List of latest transactions for each holding click on a transaction to see Nicholas A.J. Botwood's performance on stock
You May Also Like
Nicholas A.J. Botwood insider profile FAQ
What is the percentage of profitable transactions made by Nicholas A.J. Botwood?
The percentage of profitable transactions made by Nicholas A.J. Botwood is ―.
What is the average return per transaction made by Nicholas A.J. Botwood?
The average return per transaction made by Nicholas A.J. Botwood is ―.
What stocks does Nicholas A.J. Botwood hold?
Nicholas A.J. Botwood holds: SNDX stocks.
What was Nicholas A.J. Botwood’s latest transaction?
Nicholas A.J. Botwood latest transaction was an Informative Buy of $105.77K.
What was Nicholas A.J. Botwood's most profitable transaction?
Nicholas A.J. Botwood’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Nicholas A.J. Botwood's role in Syndax Pharmaceuticals?
Nicholas A.J. Botwood's role in Syndax Pharmaceuticals is Head of R&D, CMO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.